From: Probiotics in prevention and treatment of obesity: a critical view
Study | Type of study | Type of probiotics | Duration of intervention | Key findings |
---|---|---|---|---|
Kadooka et al. 2010 [72] | multicenter, double-blind, randomized, placebo-controlled trial | Lactobacillus gasseri SBT2055 | 12 weeks | ↓ abdominal visceral (on 4.6 %) and subcutaneous (3,3 %) fat areas as measured by CT ↓ body weight and BMI (on 1.5 %) ↑ serum adiponectin |
Luoto et al. 2013 [50] | randomized, double-blind, prospective follow-up study | Lactobacillus rhamnosus GG | Mothers 4 weeks before expected delivery with extension for 6 months postnatally (in children) | ↓ weight gain during the first years of life - most pronounced changes were observed at the age of 4 years (P = 0.063), with lack of efficiency in the later stages of development |
Vrieze et al. 2012 [75] | randomized, double-blind, parallel, placebo-controlled trial (FATLOSE trial) | allogenic microbiota from lean donors to male recipients with metabolic syndrome or autologous microbiota | 12 weeks | ↑ insulin sensitivity (6 weeks after infusion) ↑levels of butyrate-producing intestinal microbiota. |
Mazloom et al. 2013 [76] | randomized, single- blinded, placebo-controlled trial | Lactobacillus acidophilus, L. bulgaricus, L. bifidum, and L. casei | 6 weeks | ↓ triglyceride ↓ malondialdehyde (MDA) ↓IL-6 and ↓insulin resistance All changes not statistically significant |
Aller et al. 2011 [78] | randomized, double-blind, parallel, placebo-controlled trial | Lactobacillus bulgaricus vs Streptococcus thermophilus | 3 month | ↓ liver aminotransferases levels in patients with NAFLD Anthropometric parameters and cardiovascular risk factors remained unchanged |
Malaguarnera et al. 2012 [79] | open label study in patients with NASH | Bifidobacterium longum in combination with fructo-oligosaccharides (Fos) versus life style modification | 24 weeks | Bifidobacterium longum with Fos when compared to lifestyle modification alone, significantly reduces TNF-α, CRP, serum AST levels, HOMA-IR, serum endotoxin, steatosis, and the NASH activity index. |
Wong et al. 2013 [80] | randomized, open label study in patients with histology-proven NASH | Lepicol probiotic formula vs usual care | 6 month | ↓ intrahepatic triglyceride content (IHTG) ↓ AST level No changes in BMI, waist circumference, glucose and lipid levels |
Vajro et al. 2011 [81] | double-blind, placebo-controlled pilot study in pediatric NAFLD | Lactobacillus rhamnosus strain GG | 8 weeks | ↓ALT TNF-α and US bright liver parameters remained fairly stable |
Mykhalchyshyn et al. 2013 [83] | open label study in patients with NAFLD | “Symbiter” containing concentrated biomass of 14 alive probiotic bacteria | 4 weeks | ↓ IL-6, IL-8, TNF-α, IL-1β, IFN-γ (in elevated transaminases sub-group) ↓ IL-6, IL-8, TNF-α, (in normal transaminases sub-group) |
Shavakhi et al. 2013 [84] | randomized, double-blind, placebo-controlled trial in patients with histology-proven NASH | probiotic Protexin plus Metformin 500 mg (Met/Pro) versus Metformin 500 mg plus placebo(Met/P) | 6 month | Probiotic combination with Metformin improves liver aminotransferases better than metformin alone. BMI, fasting blood glucose, cholesterol, and triglyceride fell significantly in both groups. |